0000000000742172

AUTHOR

Ilaria Dal Forno

showing 2 related works from this author

Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part one

2017

lcsh:Diseases of the musculoskeletal systemlcsh:RJ1-570lcsh:Pediatricslcsh:RC925-935Meeting Abstracts
researchProduct

Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: Results from the GISEA register

2014

Abstract Introduction Rituximab (RTX) is a monoclonal anti-CD20 antibody approved for the treatment of rheumatoid arthritis (RA) in association with methotrexate (MTX). Objectives To evaluate the efficacy and safety of RTX–MTX combination therapy compared with RTX alone in the treatment of RA. Methods We analyzed data from a prospective cohort study, the Italian biologic register GISEA, to investigate the efficacy and safety of rituximab. Moreover, the adverse events (AE) and the causes of discontinuation therapy were analyzed. Results We identified 338 RA patients, 162 treated with RTX and 176 with RTX–MTX. After 52 and 104 weeks of therapy the disease activity score in 28 joints and the H…

RegistrieMaleanti-CD20 rituximab; rheumatoid arthritis; GISEArheumatoid arthritisSettore MED/16 - REUMATOLOGIAAnti-CD20Arthritis RheumatoidAntibodies Monoclonal Murine-DerivedRheumatoidMonoclonalRegistriesProspective cohort studyGISEAAnti-CD20; Methotrexate; Rheumatoid arthritis; Rituximab; Adult; Aged; Antibodies Monoclonal; Antibodies Monoclonal Murine-Derived; Antirheumatic Agents; Arthritis Rheumatoid; Drug Therapy Combination; Female; Humans; Male; Methotrexate; Middle Aged; Treatment Outcome; RegistriesAntirheumatic AgentAntibodies MonoclonalMiddle AgedTreatment OutcomeRituximab rheumatoid arthritisAntirheumatic AgentsRheumatoid arthritisCombinationMonoclonalDrug Therapy CombinationFemaleRituximabRituximabHumanmedicine.drugmusculoskeletal diseasesAdultMurine-Derivedmedicine.medical_specialtyCombination therapyAntibodiesNOAnti-CD20; Methotrexate; Rheumatoid arthritis; RituximabDrug TherapyRheumatologyanti-CD20 rituximabInternal medicinemedicineHumansRheumatoid arthritisAdverse effectRheumatoid arthritiAnti-CD20; Methotrexate; Rheumatoid arthritis; Rituximab; Adult; Aged; Antibodies Monoclonal; Antibodies Monoclonal Murine-Derived; Antirheumatic Agents; Arthritis Rheumatoid; Drug Therapy Combination; Female; Humans; Male; Methotrexate; Middle Aged; Rituximab; Treatment Outcome; Registries; RheumatologyAgedbusiness.industryArthritismedicine.diseaseSurgeryDiscontinuationMethotrexateMethotrexatebusinessJoint Bone Spine
researchProduct